目的 探討果糖二磷酸鈉聯(lián)合奧拉西坦治療急性顱腦損傷的安全性與有效性。方法 選取2017年9月-2018年9月在漯河市中心醫(yī)院就診的急性顱腦損傷患者101例，隨機(jī)將患者分成對(duì)照組（50例）和治療組（51例）兩組。對(duì)照組患者口服奧拉西坦膠囊，2粒/次，3次/d。治療組患者在對(duì)照組基礎(chǔ)上口服果糖二磷酸鈉片，4片/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者格拉斯哥昏迷指數(shù)（GCS）評(píng)分、國(guó)立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分，及血清Tau蛋白、S100β蛋白和人低氧誘導(dǎo)因子-1α（HIF-1α）水平。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為78.00%、94.12%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者GCS評(píng)分顯著升高，NIHSS評(píng)分顯著降低（P<0.05），且治療組比對(duì)照組改善的更顯著（P<0.05）。治療后，兩組患者血清Tau蛋白、S100β蛋白以及HIF-1α水平均顯著降低（P<0.05），且治療組患者明顯低于對(duì)照組（P<0.05）。結(jié)論 果糖二磷酸鈉聯(lián)合奧拉西坦治療急性顱腦損傷療效顯著、安全性高，且能夠顯著改善患者昏迷狀態(tài)與神經(jīng)功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the safety and efficacy of fructose diphosphate sodium combined with oxiracetam in treatment of acute craniocerebral injury. Methods Patients (101 cases) with acute craniocerebral injury in Luohe Central Hospital from September 2017 to September 2018 were randomly divided into control (50 cases) and treatment (51 cases) groups. Patients in the control group were po administered with Oxiracetam Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Fructose Diphosphate Sodium Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the GCS and NIHSS scores, the serum levels of Tau protein, S100β protein and HIF-1α in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 78.00% and 94.12%, respectively, and there were differences between two groups (P<0.05). After treatment, the GCS scores in two groups were significantly increased, but the NIHSS scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of Tau protein, S100β protein and HIF-1α in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Fructose diphosphate sodium combined with oxiracetam is effective and safe in treatment of acute craniocerebral injury, can significantly improve the comatose state and nerve function, which has a certain clinical application value.

R971